Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

New England Journal of Medicine · Published 2026-07-22 · DOI 10.1056/nejmoa2601486

Authors (27)

Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, Albert Font, Tudor Ciuleanu, Jonathan Chatzkel, Takuya Koie, Christopher J. Hoimes, Javier Puente, Yousef Zakharia, Eli Rosenbaum, Katharina Boehm, Yohann Loriot, Jens Bedke, Thomas B. Powles, Andrea Necchi, Pawel Wiechno, Carlos Álvarez-Fernández, Tae-Hwan Kim, Niara Oliveira, Thomas W. Flaig, Heidi S. Wirtz, Michael Mihm, Qinlei Huang, Aljosja Rogiers, Blanca Homet Moreno, Alfonso Gómez de Liaño

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Galsky, M., Valderrama, B., Maruzzo, M., et al. (2026). Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2601486

Related articles